<?xml version='1.0' encoding='utf-8'?>
<document id="26178713"><sentence text="Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation."><entity charOffset="31-39" id="DDI-PubMed.26178713.s1.e0" text="imatinib" /></sentence><sentence text="Inducers and inhibitors of CYP3A, such as ritonavir and efavirenz, may be used as part of the highly active antiretroviral therapy (HAART) to treat HIV patients"><entity charOffset="42-51" id="DDI-PubMed.26178713.s2.e0" text="ritonavir" /><entity charOffset="56-65" id="DDI-PubMed.26178713.s2.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.26178713.s2.e0" e2="DDI-PubMed.26178713.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26178713.s2.e0" e2="DDI-PubMed.26178713.s2.e1" /></sentence><sentence text=" HIV patients with chronic myeloid leukemia or gastrointestinal stromal tumour may need imatinib, a CYP3A4 substrate with known exposure response-relationships"><entity charOffset="88-96" id="DDI-PubMed.26178713.s3.e0" text="imatinib" /></sentence><sentence text=" Administration of imatinib to patients on ritonavir or efavirenz may result in altered imatinib exposure leading to increased toxicity or failure of therapy, respectively"><entity charOffset="19-27" id="DDI-PubMed.26178713.s4.e0" text="imatinib" /><entity charOffset="43-52" id="DDI-PubMed.26178713.s4.e1" text="ritonavir" /><entity charOffset="56-65" id="DDI-PubMed.26178713.s4.e2" text="efavirenz" /><entity charOffset="88-96" id="DDI-PubMed.26178713.s4.e3" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e0" e2="DDI-PubMed.26178713.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e0" e2="DDI-PubMed.26178713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e0" e2="DDI-PubMed.26178713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e0" e2="DDI-PubMed.26178713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e1" e2="DDI-PubMed.26178713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e1" e2="DDI-PubMed.26178713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e1" e2="DDI-PubMed.26178713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e2" e2="DDI-PubMed.26178713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s4.e2" e2="DDI-PubMed.26178713.s4.e3" /></sentence><sentence text=" We used primary human hepatocyte cultures to evaluate the magnitude of interaction between imatinib and ritonavir/efavirenz"><entity charOffset="92-100" id="DDI-PubMed.26178713.s5.e0" text="imatinib" /><entity charOffset="105-114" id="DDI-PubMed.26178713.s5.e1" text="ritonavir" /><entity charOffset="115-124" id="DDI-PubMed.26178713.s5.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.26178713.s5.e0" e2="DDI-PubMed.26178713.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26178713.s5.e0" e2="DDI-PubMed.26178713.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s5.e0" e2="DDI-PubMed.26178713.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s5.e1" e2="DDI-PubMed.26178713.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s5.e1" e2="DDI-PubMed.26178713.s5.e2" /></sentence><sentence text="" /><sentence text="Hepatocytes were pre-treated with vehicle, ritonavir, ketoconazole, efavirenz or rifampicin, and the metabolism of imatinib was characterized over time"><entity charOffset="43-52" id="DDI-PubMed.26178713.s7.e0" text="ritonavir" /><entity charOffset="54-66" id="DDI-PubMed.26178713.s7.e1" text="ketoconazole" /><entity charOffset="68-77" id="DDI-PubMed.26178713.s7.e2" text="efavirenz" /><entity charOffset="81-91" id="DDI-PubMed.26178713.s7.e3" text="rifampicin" /><entity charOffset="115-123" id="DDI-PubMed.26178713.s7.e4" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e0" e2="DDI-PubMed.26178713.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e0" e2="DDI-PubMed.26178713.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e0" e2="DDI-PubMed.26178713.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e0" e2="DDI-PubMed.26178713.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e0" e2="DDI-PubMed.26178713.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e1" e2="DDI-PubMed.26178713.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e1" e2="DDI-PubMed.26178713.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e1" e2="DDI-PubMed.26178713.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e1" e2="DDI-PubMed.26178713.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e2" e2="DDI-PubMed.26178713.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e2" e2="DDI-PubMed.26178713.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e2" e2="DDI-PubMed.26178713.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e3" e2="DDI-PubMed.26178713.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s7.e3" e2="DDI-PubMed.26178713.s7.e4" /></sentence><sentence text=" Concentrations of imatinib and metabolite were quantitated in combined lysate and medium, using LC-MS"><entity charOffset="19-27" id="DDI-PubMed.26178713.s8.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="The predicted changes in imatinib CLoral (95% CI) with ketoconazole, ritonavir, rifampicin and efavirenz were 4"><entity charOffset="25-33" id="DDI-PubMed.26178713.s10.e0" text="imatinib" /><entity charOffset="46-48" id="DDI-PubMed.26178713.s10.e1" text="CI" /><entity charOffset="55-67" id="DDI-PubMed.26178713.s10.e2" text="ketoconazole" /><entity charOffset="69-78" id="DDI-PubMed.26178713.s10.e3" text="ritonavir" /><entity charOffset="80-90" id="DDI-PubMed.26178713.s10.e4" text="rifampicin" /><entity charOffset="95-104" id="DDI-PubMed.26178713.s10.e5" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e0" e2="DDI-PubMed.26178713.s10.e5" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e1" e2="DDI-PubMed.26178713.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e1" e2="DDI-PubMed.26178713.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e1" e2="DDI-PubMed.26178713.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e1" e2="DDI-PubMed.26178713.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e1" e2="DDI-PubMed.26178713.s10.e5" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e2" e2="DDI-PubMed.26178713.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e2" e2="DDI-PubMed.26178713.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e2" e2="DDI-PubMed.26178713.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e2" e2="DDI-PubMed.26178713.s10.e5" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e3" e2="DDI-PubMed.26178713.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e3" e2="DDI-PubMed.26178713.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e3" e2="DDI-PubMed.26178713.s10.e5" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e4" e2="DDI-PubMed.26178713.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26178713.s10.e4" e2="DDI-PubMed.26178713.s10.e5" /></sentence><sentence text="0-fold (0, 9" /><sentence text="2) lower, 2" /><sentence text="8-fold (0" /><sentence text="04, 5" /><sentence text="5) lower, 2" /><sentence text="9-fold (2" /><sentence text="2, 3" /><sentence text="5) higher and 2" /><sentence text="0-fold (0" /><sentence text="42, 3" /><sentence text="5) higher, respectively" /><sentence text=" These predictions were in good agreement with clinical single dose drug-drug interaction studies, but not with reports of imatinib interactions at steady-state"><entity charOffset="123-131" id="DDI-PubMed.26178713.s22.e0" text="imatinib" /></sentence><sentence text=" Alterations in metabolism were similar after acute or chronic imatinib exposure"><entity charOffset="63-71" id="DDI-PubMed.26178713.s23.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="In vitro human hepatocytes predicted increased clearance of imatinib with inducers and decreased clearance with inhibitors of CYP enzymes"><entity charOffset="60-68" id="DDI-PubMed.26178713.s25.e0" text="imatinib" /></sentence><sentence text=" The impact of HAART on imatinib may depend on whether it is being initiated or has already been dosed chronically in patients"><entity charOffset="24-32" id="DDI-PubMed.26178713.s26.e0" text="imatinib" /></sentence><sentence text=" Therapeutic drug monitoring may have a role in optimizing imatinib therapy in this patient population"><entity charOffset="59-67" id="DDI-PubMed.26178713.s27.e0" text="imatinib" /></sentence><sentence text="" /></document>